The U.S. Food and Drug Administration has initiated a voluntary recall of millions of duloxetine delayed-release capsules, commonly prescribed for depression, anxiety, and chronic pain conditions. The medication—sold under the brand name Cymbalta—is being pulled from shelves due to elevated levels of N-nitroso-duloxetine, a compound classified as a probable human carcinogen by the FDA.

Manufacturer Towa Pharmaceutical and its U.S. distributor, Breckenridge Pharmaceuticals, have recalled both 30mg and 60mg doses of the generic formulation. Approximately 370,000 bottles affected by this Class II recall were identified through lot codes including 241180C (expiring April 2027) and others listed in official FDA notices. The recall was triggered because detected nitrosamine levels surpassed federal safety thresholds.

Nitrosamines—chemicals previously linked to widespread recalls of blood pressure medications and heartburn drugs like Zantac—form through interactions between preservatives and amines during manufacturing, storage, or handling. While no adverse effects have been reported for the recalled products, abrupt discontinuation of duloxetine under medical supervision may cause withdrawal symptoms. Patients must consult their healthcare provider before adjusting medication regimens.

The FDA emphasizes that exposure to this product may cause temporary or medically reversible health consequences, though serious risks remain unlikely. The affected lots include specific packaging details across multiple dosages and quantities as detailed in the official recall notice. Consumers should not use recalled products and should contact their pharmacy for guidance on safe alternatives.